Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2196044 · 1 trial · 1 indication
The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the number of heavy drinking days. Heavy drinking is defined as ≥4 drinks/day for women and ≥5 drinks/day for men. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.
| Arm | Type | Description |
|---|---|---|
| LY2196044 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| LY2196044 | DRUG | 250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks |
| placebo | DRUG | once daily, orally, 16 weeks |
Inclusion Criteria: * Have Alcohol Dependence. Subjects must manifest at least the following 3 requirements for their diagnosis of Alcohol Dependence: 1. Be tolerant, as defined by either of the following: 1. A need for markedly increased amounts of alcohol to achieve intoxication or desir...
LY2196044 is an investigational small molecule being studied for the treatment of alcohol dependence. It is being developed by Eli Lilly and Company for this psychiatric condition. The drug is currently in Phase 2 clinical development and is not approved for any use.
LY2196044 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research on this investigational drug for the treatment of alcohol dependence.
LY2196044 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial for the treatment of alcohol dependence has been completed, with no active trials currently ongoing.
LY2196044 has one completed clinical trial registered as NCT00804570, titled "A Study for the Treatment of Alcohol Dependence." This Phase 2 study enrolled 375 participants in the United States, was randomized, double-blind, and placebo-controlled, and included adults aged 21 years and older.
LY2196044 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of alcohol dependence. The drug has completed one clinical trial but has not yet received regulatory approval for any indication.